News >

Expert Discusses Docetaxel Versus Abiraterone in Hormone-Sensitive Prostate Cancer

Caroline Seymour
Published: Wednesday, Feb 14, 2018

William Oh, MD

William Oh, MD
The management of metastatic hormone-sensitive prostate cancer continues to evolve as new findings emerge, such as results from the LATITUDE and CHAARTED studies.

, William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor, Medicine and Urology, Mount Sinai School of Medicine, associate director, Clinical Research, The Tisch Cancer Institute, discussed treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

OncLive: What questions surround abiraterone versus docetaxel in the treatment in prostate cancer?

Oh: One of the biggest developments in the treatment of advanced prostate cancer over the past several years has been the management of metastatic hormone-sensitive prostate cancer. This is primarily in patients who are newly diagnosed. In 2014, a plenary session at the ASCO Annual Meeting presented the results of CHAARTED. The results, favoring the use of early chemotherapy, were subsequently published in the New England Journal of Medicine. A second study, STAMPEDE, confirmed those findings. At that time, we started using docetaxel in the treatment of newly diagnosed metastatic disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication